{"denoms":[{"counts":[{"groupId":"BG000","value":"155"}],"units":"Participants"}],"groups":[{"description":"Study patients: adult patients with high grade primary malignant brain tumors or with known or suspected brain metastases from histologically confirmed primary cancer\n\nStudy procedures: patients will receive IV ferumoxytol (maximum dose 4 mg/kg, over at least 15 minutes) beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients will also undergo MRI without contrast at baseline (before and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.\n\n3 Tesla Magnetic Resonance Imaging: Undergo 3T MRI\n\nDynamic Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DCE-MRI\n\nDynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DSC-MRI\n\nFerumoxytol: Given IV\n\nGadolinium: Given IV\n\nMRI-Based Angiogram: Undergo MRA","id":"BG000","title":"Malignant Brain Tumor Patients Undergoing Brain MRI (With Both Ferumoxytol and Gadolinium)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.81","value":"51.71"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"85"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"150"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"147"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67"}],"title":"Glioblastoma"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Anaplastic Astrocytoma"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Anaplastic Oligodendroglioma"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Primary CNS Lymphoma"},{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Brain metastasis"},{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Type of brain malignancy","unitOfMeasure":"Participants"}]}